REGULATORY
EMA Confirms Usefulness of Pioglitazone-Containing Medicines as 2nd, 3rd Line Treatment Options: Takeda
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) clarified on October 21 the label changes for the type 2 diabetes treatment Actos (pioglitazone) and for pioglitazone-containing medicines from Takeda Pharmaceutical, and confirmed a…
To read the full story
REGULATORY
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





